Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Sureda

Showing results (261-270 of 335) with videos related to

Pageof 34
Sort By:
Blood|September 9, 2011
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenanceMaría-Victoria Mateos, Norma C Gutiérrez, María-Luisa Martín-Ramos, et al.
Haematologica|April 27, 2023
Randomized phase II study of weekly carfilzomib 70 mg/m<sup>2</sup> and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patientsBorja Puertas, Verónica González-Calle, Anna Sureda, et al.
Bone Marrow Transplantation|March 1, 2023
SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccinationJosé Luis Piñana, Rodrigo Martino, Lourdes Vazquez, et al.
Journal for Immunotherapy of Cancer|July 7, 2026
Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphomaFarrukh T Awan, Joshua T Gamse, Marije B Overdijk, et al.
Journal of Hematology & Oncology|May 7, 2022
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disordersJosé Luis Piñana, Lucia López-Corral, Rodrigo Martino, et al.
The New England Journal of Medicine|June 5, 2023
Survival with Axicabtagene Ciloleucel in Large B-Cell LymphomaJason R Westin, Olalekan O Oluwole, Marie José Kersten, et al.
Blood Cancer Journal|October 20, 2020
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortalityJoaquín Martínez-López, María-Victoria Mateos, Cristina Encinas, et al.
Bone Marrow Transplantation|October 7, 2024
Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow TransplantationMohamed Amine Bekadja, Dietger Niederwiser, Mohamed A Kharfan-Dabaja, et al.
Blood|July 28, 2023
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myelomaLaura Rosiñol, Albert Oriol, Rafael Ríos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple MyelomaJuan-Jose Garcés, Maria-Teresa Cedena, Noemi Puig, et al.
Pageof 34

Showing results (261-270 of 335) with videos related to

Sort By:
Pageof 34
Blood|September 9, 2011
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenanceMaría-Victoria Mateos, Norma C Gutiérrez, María-Luisa Martín-Ramos, et al.
Haematologica|April 27, 2023
Randomized phase II study of weekly carfilzomib 70 mg/m<sup>2</sup> and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patientsBorja Puertas, Verónica González-Calle, Anna Sureda, et al.
Bone Marrow Transplantation|March 1, 2023
SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccinationJosé Luis Piñana, Rodrigo Martino, Lourdes Vazquez, et al.
Journal for Immunotherapy of Cancer|July 7, 2026
Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphomaFarrukh T Awan, Joshua T Gamse, Marije B Overdijk, et al.
Journal of Hematology & Oncology|May 7, 2022
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disordersJosé Luis Piñana, Lucia López-Corral, Rodrigo Martino, et al.
The New England Journal of Medicine|June 5, 2023
Survival with Axicabtagene Ciloleucel in Large B-Cell LymphomaJason R Westin, Olalekan O Oluwole, Marie José Kersten, et al.
Blood Cancer Journal|October 20, 2020
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortalityJoaquín Martínez-López, María-Victoria Mateos, Cristina Encinas, et al.
Bone Marrow Transplantation|October 7, 2024
Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow TransplantationMohamed Amine Bekadja, Dietger Niederwiser, Mohamed A Kharfan-Dabaja, et al.
Blood|July 28, 2023
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myelomaLaura Rosiñol, Albert Oriol, Rafael Ríos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple MyelomaJuan-Jose Garcés, Maria-Teresa Cedena, Noemi Puig, et al.
Pageof 34